{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:16:41Z","timestamp":1788293801945,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euros.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:57:58Z","timestamp":1785434278000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prostate Cancer Mortality in Men not Attending a Population-based Screening Program: The \u2018Good\u2019, the \u2018Bad\u2019, and the \u2018Ugly\u2019 After 20-yr Follow-up in the European Randomised study of Screening for Prostate Cancer"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4561-562X","authenticated-orcid":false,"given":"Ren\u00e9e C.A.","family":"Leenen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esm\u00e9e F.H.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Remmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo I.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Arnsrud-Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly Den","family":"Hond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Villers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Pionas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Llane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Lujan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donella","family":"Puliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bangma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz H.","family":"Schroder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.06.009_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.06.009_b0010","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.06.009_b0015","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.06.009_b0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eururo.2024.07.019","article-title":"Prostate cancer early detection in the European Union and UK","volume":"87","author":"Leenen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0025","unstructured":"EUCanScreen. European joint action on cancer screening; 2024, https:\/\/www.dypede.gr\/eucanscreen\/."},{"key":"10.1016\/j.euros.2026.06.009_b0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2023.08.002","article-title":"Early detection of prostate cancer in the European Union: combining forces with PRAISE-U","volume":"84","author":"Van Poppel","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0035","unstructured":"World Health Organization. A short guide to cancer screening: increase effectiveness, maximize benefits and minimize harm; 2022. https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289057561."},{"key":"10.1016\/j.euros.2026.06.009_b0040","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2026.06.009_b0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/21681805.2021.1881612","article-title":"The G\u00d6TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate","volume":"55","author":"Kohestani","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","article-title":"Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men","volume":"85","author":"Bratt","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0055","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.06.009_b0060","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2026.06.009_b0065","unstructured":"Eurostat. Cancer screening statistics; updated 2024, https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Cancer_screening_statistics."},{"key":"10.1016\/j.euros.2026.06.009_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085029","article-title":"First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study","volume":"390","author":"Ma","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2026.06.009_b0075","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.06.009_b0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1465-5101.2003.04402.x","article-title":"Determining the cause of death in randomized screening trial(s) for prostate cancer","volume":"92(Suppl. 2)","author":"De Koning","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.06.009_b0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.23126","article-title":"Assessment of causes of death in a prostate cancer screening trial","volume":"122","author":"M\u00e4kinen","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2026.06.009_b0095","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/aje\/kww084","article-title":"Prostate cancer and socioeconomic status in the Finnish randomized study of screening for prostate cancer","volume":"184","author":"Kilpel\u00e4inen","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euros.2026.06.009_b0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/pubmed\/22.3.312","article-title":"Why do men refuse or attend population-based screening for prostate cancer?","volume":"22","author":"Nijs","year":"2000","journal-title":"J Public Health"},{"key":"10.1016\/j.euros.2026.06.009_b0110","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1002\/cncr.24680","article-title":"Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees","volume":"115","author":"Bergdahl","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2026.06.009_b0115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1464-410X.2010.09165.x","article-title":"Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial","volume":"106","author":"Malmi","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.06.009_b0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/epirev\/mxq018","article-title":"Psychosocial determinants of socioeconomic inequalities in cancer screening participation: a conceptual framework","volume":"33","author":"von Wagner","year":"2011","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.euros.2026.06.009_b0125","article-title":"Determinants of non-participation in population-based breast cancer screening: a systematic review and meta-analysis","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2026.06.009_b0130","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/pon.5997","article-title":"Factors promoting breast, cervical and colorectal cancer screenings participation: a systematic review","volume":"31","author":"Vallone","year":"2022","journal-title":"Psychooncology"},{"key":"10.1016\/j.euros.2026.06.009_b0135","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/eurpub\/ckaa203","article-title":"Inequalities and risk factors related to non-participation in colorectal cancer screening programmes: a systematic review","volume":"31","author":"Unanue-Arza","year":"2021","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.euros.2026.06.009_b0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2340\/1651-226X.2025.43399","article-title":"Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity","volume":"64","author":"Str\u00f6mberg","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euros.2026.06.009_b0145","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamainternmed.2018.5982","article-title":"Association of nonadherence to cancer screening examinations with mortality from unrelated causes: a secondary analysis of the PLCO cancer screening trial","volume":"179","author":"Pierre-Victor","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euros.2026.06.009_b0150","first-page":"461","article-title":"Social determinants of health and US cancer screening interventions: a systematic review","volume":"73","author":"Korn","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2026.06.009_b0155","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ije\/dyq003","article-title":"Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program","volume":"39","author":"Pal\u00e8ncia","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.euros.2026.06.009_b0160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/annonc\/mdr121","article-title":"Does an organised screening programme reduce the inequalities in breast cancer survival?","volume":"23","author":"Puliti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.06.009_b0165","article-title":"Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men","volume":"3","author":"J\u00e4rbur","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.euros.2026.06.009_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0322643","article-title":"Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: a register-based study of 50-year-old men","volume":"20","author":"J\u00e4rbur","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.euros.2026.06.009_b0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ypmed.2010.01.007","article-title":"The impact of interventions to improve attendance in female cancer screening among lower socioeconomic groups: a review","volume":"50","author":"Spadea","year":"2010","journal-title":"Prev Med"},{"key":"10.1016\/j.euros.2026.06.009_b0180","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/ijc.25278","article-title":"Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)","volume":"127","author":"Kerkhof","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2026.06.009_b0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2017.01.048","article-title":"Estimate of opportunistic prostate specific antigen testing in the Finnish randomized study of screening for prostate cancer","volume":"198","author":"Kilpel\u00e4inen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1464-410X.2003.04407.x","article-title":"Contamination by opportunistic screening in the European randomized study of prostate cancer screening","volume":"92(Suppl. 2)","author":"Ciatto","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.06.009_b0195","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JU.0000000000002835","article-title":"Prostate specific antigen and biopsy contamination in the G\u00f6teborg-1 randomized, population-based, prostate cancer screening trial","volume":"208","author":"Stinesen Kollberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0200","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V","article-title":"Adjusting for non-compliance and contamination in randomized clinical trials","volume":"16","author":"Cuzick","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.euros.2026.06.009_b0205","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2009.07.018","article-title":"Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)","volume":"56","author":"Roobol","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2013.08.005","article-title":"Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer","volume":"65","author":"Bokhorst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.009_b0215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ijc.32129","article-title":"Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer","volume":"145","author":"Lindberg","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2026.06.009_b0220","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/ijc.29300","article-title":"The Finnish prostate cancer screening trial: analyses on the screening failures","volume":"136","author":"Kilpel\u00e4inen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2026.06.009_b0225","article-title":"Interventions targeted at women to encourage the uptake of cervical screening","volume":"9","author":"Staley","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euros.2026.06.009_b0230","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s11606-024-09097-8","article-title":"Efficacy of interventions intended to increase lung cancer screening rates: a systematic review and meta-analysis","volume":"40","author":"Satoh","year":"2025","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.euros.2026.06.009_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/phrs.2025.1607873","article-title":"Advancing mammographic screening among underserved groups: a systematic review and meta-analysis of intervention strategies to increase breast cancer screening uptake","volume":"46","author":"Ferrari","year":"2025","journal-title":"Public Health Rev"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:43:26Z","timestamp":1788291806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S2666168326006464"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.06.009","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Mortality in Men not Attending a Population-based Screening Program: The \u2018Good\u2019, the \u2018Bad\u2019, and the \u2018Ugly\u2019 After 20-yr Follow-up in the European Randomised study of Screening for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}